AAIITO Expert Consensus Reframes Mild-to-Moderate Asthma Toward Proactive Control

An Italian Delphi and RAND/UCLA consensus pushes pharmacists toward proactive, phenotype-informed, ICS-containing regimens rather than symptom-driven reliever use in mild-to-moderate asthma.

Expert consensus on Management of Mild and Moderate AsthmaAAIITOmild-to-moderate asthmainhaled corticosteroidsICS/LABAbiomarkersFeNOeosinophils Pulmonology / Respiratory

Background Information

Expert consensus offers new guidelines for mild-to-moderate asthma management.

Mild and moderate asthma often remain poorly controlled, leading to exacerbations and limitations in daily activities. Consensus on asthma management includes optimal control without symptoms and exacerbations, using personalized treatment and patient education. These consensus guidelines provide practical recommendations validated for clinical appropriateness to improve asthma management and control. A proactive, patient-centric approach is key to managing mild-to-moderate asthma effectively.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Martini M, Cecchi L, Musarra A, Jaubashi K, Marra AM, Murzilli F, Papia F, Valenti G, Yang B, Cazzola M, Vaghi A, Bilò MB

Citation: Martini M, Cecchi L, Musarra A, et al. Expert consensus on the Management of Mild and Moderate Asthma. Respiratory medicine. 2026:109078. doi:10.1016/j.rmed.2026.109078

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →